Clinical and acquired conditions
Thrombus formation and thrombus growth are the results of vascular injury and local coagulation activation combined with a disturbance in the balance between coagulation and fibrinolysis, leading to a prothrombotic state. Numerous conditions, such as peripartal asphyxia, fetal diabetes, neonatal infections, dehydration, the use of central lines, trauma or surgery, malignant diseases, renal diseases, autoimmune diseases, the administration of coagulation factor concentrates, or the intake of oral contraceptives in adolescent girls result in elevated thrombin generation with subsequent thrombus formation in infancy and childhood (Table 1) In neonates, the most common manifestations of vascular occlusion are thrombosis of the renal veins and the vena cava, and peripartal thromboembolic stroke (Table  2 ). In addition, high rates of catheter-related thrombosis in neonates, infants, and children have been reported. Central venous lines lead to thrombus formation and thrombus growth near the catheter implantation site, especially when prothrombotic risk factors are involved. Further sources of childhood thromboembolism reported are cerebral venous thrombosis, intracardiac thrombosis, portal and mesenteric vein thrombosis, vascular occlusions of the deep limb veins, and pulmonary embolism.
Arterial vascular occlusions
Arterial vascular occlusions besides thromboembolic ischemic stroke have been reported, mainly as catheterrelated thrombosis in the aorta, femoral artery, mesenteric arteries, and subclavian artery, respectively [2-9].
Inherited genetic disorders
Various genetic defects, particularly those affecting the physiologic anticoagulant systems, ie, antithrombin-, protein C-, and protein S-deficiency; resistance to activated protein C (APC-R) mostly because of the G1691A mutation of coagulation factor V, and the prothrombin G20210A gene variant, have been established as risk factors for thrombotic events not only in adults [20] (Table 3) . Metabolic diseases such as homozygous homocysteinuria, and moderate hyperhomocysteinemia because of malnutrition or the common homozygous TT genotype of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism have been described, as well as increased concentrations of lipoprotein (Lp)(a), fibrinogen, factor VIIIC, and factor IX, or factor XII-deficiency, which have been shown to enhance the risk of thromboembolic arterial and venous thrombosis in pediatric or adult patients. In addition, infants with acute purpura fulminans because of homozygous protein C deficiency or protein S deficiency have been reported. The prothrombotic risk factors reported are not only involved in pediatric venous or arterial thromboembolism but also in intraventricular hemorrhage in preterm infants [ 
Screening for risk factors Population background
The distribution of prothrombotic risk factors varies in different countries with respect to the ethnic background and the number of patients/controls investigated. Thus, to estimate the individual patient risk in pediatric patients suffering thromboembolism, it is recommended that symptomatic patients be investigated in comparison with age-and gender-matched healthy controls with attention to ethnicity [49] [50] [51] .
Patients who should be screened
Children with symptomatic thrombosis should be treated by pediatricians with special expertise in coagulation. A recent prospective study has indicated that the subgroup of pediatric patients suffering from multiple combined prothrombotic risk factors is at risk of thrombus recurrence after an initial event of spontaneous venous thromboembolism. Therefore, laboratory testing for multiple risk factors is warranted in symptomatic children [25••] . In addition, the availability of effective prophylactic anticoagulation around high-risk events such as elective surgery supports a discussion of genetic screening in asymptomatic siblings and other first-degree relatives of an affected child [52•].
Laboratory investigation and interpretation of results
To identify prothrombotic risk factors and underlying conditions responsible for thrombosis diseases in children, in addition to a comprehensive personal and family history a laboratory work-up (Table 3) is indicated. Besides genotyping at the onset of the thrombotic disease, a step-wise diagnostic procedure is recommended for plasma-based parameters. In pediatric patients with a reduced protein activity, total protein concentration and free antigen (protein S only) should be determined. To prevent results of protein-based assays from being affected by the acute thrombotic onset, plasma samples should be obtained at least 3 to 6 months after the thrombotic episode. In addition, oral anticoagulant medication also influences protein-based assays. Therefore it is recommended that fresh plasma samples for coagulation analyses be drawn at least 14 to 30 days after withdrawal of oral anticoagulation. Data interpretation is based on age-dependent reference ranges or the identification of causative gene mutations/polymorphisms with respect to individual ethnic backgrounds [49-54].
Treatment modalities
In pediatric patients with thromboembolism, detailed patient management is seriously hampered by the lack of appropriate clinical trials. In addition, long-term outcome of pediatric thromboembolism has rarely been reported to date [55-57,57•]. Thus, until data are available for the treatment of symptomatic children, pediatric patients with thrombosis are treated according to recommendations based on small-scale studies in children and guidelines adapted from adult patient protocols. Besides specific treatment of acute thromboembolism with anticoagulant or thrombolytic therapy (catheter-and non-catheter-related thrombosis), infants with acute purpura fulminans caused by homozygous protein C deficiency or protein S deficiency should receive fresh frozen plasma or, if available, protein C concentrate [70] . In addition, to prevent pulmonary embolism in selected cases the use of cava filters has been reported [71•]. The latter, however, is difficult and risky in small neonates, infants, and children. As in adults, it must be kept in mind that heparin administration and the use of thrombolytic agents can lead to major bleeding episodes or acute thrombus rupture with subsequent pulmonary embolism or thromboembolic stroke in neonates (patent foramen ovale). In addition, heparininduced thrombocytopenia type II has not only been reported in adults but also in pediatric patients, creating the potential need to substitute heparin with an alternative anticoagulant emergently [61•]. Whereas the man- The authors demonstrated that 98% of patients investigated during a 3.5-year follow-up period had one or more risk factors with infection in 68% of cases, followed by factor V G1691A or prothrombin G20210A in 32.5% of cases. The death rate reported was 12.5% in the cohort investigated. Retrospectively it is demonstrated that heparin-induced thrombocytopenia with subsequent thrombosis occurred in 2.3% of pediatric patients exposed to heparin for more than 5 days at intensive care units. Although the incidence is similar to that of adults, the outcome is reported to be less severe. 
